AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles
This article was originally published in The Pink Sheet Daily
Executive Summary
Both AstraZeneca’s Tagrisso and Clovis’ rociletinib target metastatic EGFR T790M mutation-positive non-small cell lung cancer. Tagrisso was approved by FDA Nov. 13, while Clovis said its drug would be delayed because mature data showed fewer confirmed responses than earlier data.
You may also be interested in...
EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso
The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.
AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.